Sylvana Hassanieh, Director, Global Medical Affairs Leader in Gynecological Oncology at AstraZeneca, shared on LinkedIn:
“I’m delighted to share that I’m taking on a new role as Director, Global Medical Affairs Leader, in Gynecological Oncology at AstraZeneca, joining Bob Li’s function and Kieran Davey’s team, with a focus on our Antibody-Drug Conjugate (ADC) portfolio.
As I transition from lung cancer, where I have had the privilege of contributing to the evolving immuno-oncology strategy and landscape through Translational Medicine, I’m excited to take on a new challenge and bring that experience into Gynecological Oncology.
Having spent the past two years building experience in Global Medical Affairs across Medical and Diagnostics, I have seen first-hand the importance of this cross-functional role at the intersection of R&D, Clinical Development, Commercial and Scientific Communications. It is where scientific innovation meets clinical practice, and where evidence translates into meaningful medical strategies for patients.
There could hardly be a more exciting time to join the Gynecological Oncology team. With AstraZeneca’s growing ADC portfolio and pipeline, we have an important opportunity to shape the evolving treatment landscape:
- generating evidence to optimize ADC sequencing,
- exploring the potential of ADCs in earlier lines of treatment,
- and advancing patient selection while championing equitable access to diagnostics and treatment across healthcare systems and geographies.
I’m looking forward to working alongside an incredibly talented global team, bringing together expertise, cross-functional collaboration and a shared ambition to advance care for women living with gynecological cancers.”
You can also read: AstraZeneca Puts $2 Billion Behind Summit’s Ivonescimab, Pairing the PD-1/VEGF Bispecific With Its ADC Portfolio
